Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $21 from $66 and keeps a Buy rating on the shares. The firm updated its model following uneventful Q4 results as execution continues to be up and down and as a result the analyst adjusted thigs more conervatively than in the past. The adjustments adjustments still leave it with a valuation significantly above where shares currently trade, and as a result remain Buy rated.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Regulatory Shifts Cloud Arcturus Therapeutics’ Outlook as FDA Delays KOSTAIVE BLA and Demands New COVID-19 Efficacy Data
- Arcturus Therapeutics Balances Pipeline Progress With Cash Strain
- Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler
- Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
- Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating